## Abstract The causal relationship between persistent highβrisk human papillomavirus infection and cervical cancer is widely accepted. HRβHPV DNA testing, alone or in combination with Pap smear testing, may have a role in primary screening. The screening results (VIA, VILI, Pap, and HRβHPV DNA) of
Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo
β Scribed by Salaheddin M. Mahmud; Ghislain Sangwa-Lugoma; Samih H. Nasr; Patrick K. Kayembe; Rahma R. Tozin; Pierre Drouin; Attila Lorincz; Alex Ferenczy; Eduardo L. Franco
- Book ID
- 113963503
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 237 KB
- Volume
- 124
- Category
- Article
- ISSN
- 0090-8258
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The APTIMA V R HPV Assay (AHPV) allows detection of 14 high-risk human papillomavirus (HPV) RNA types in cervical specimens. Until present, the assay has been compared to HPV DNA tests only in triage settings. Herein, we compare AHPV with a DNA assay (Hybrid Capture V R 2; HC2) and liquid-based cyto
## Abstract Since infection with oncogenic human papillomavirus (HPV) has been considered a necessary cause of cervical cancer, tests for oncogenic HPV types have been proposed as adjuncts or replacements to Pap cytology. We designed the Canadian Cervical Cancer Screening Trial (CCCaST) to compare